News

First-quarter sales of the oral Wegovy pill hit $353 million, more than double analyst expectations, as the company lifted its full-year outlook

Novo Nordisk stock rose as it raised its guidance on the back of the strong performance of its weight-loss pill.

May 6 (Reuters) - European shares rose on Tuesday, with oil prices dropping and investor optimism rising after U.S.

VTRS gears up to report Q1 results as import alerts, regional pressures and growth in key brands shape expectations ahead of May 7 release.

NVO heads into Q1 with strong GLP-1 drug demand and new Wegovy pill rollout, but pricing pressure, weak guidance and Eli Lilly rivalry weigh on outlook.

CPRX's Q1 earnings are expected to beat estimates on strong Firdapse demand and rising Agamree sales, while Fycompa faces patent-driven pressure.

First quarter earnings season is in full swing, with a full slate of semiconductor and consumer companies slated to report results.

ZTS eyes a Q1 beat as companion animal products and international growth offset U.S. weakness ahead of its May 7 earnings report.

AMGN beats Q1 estimates as 16 drugs post double-digit growth, offsetting biosimilar erosion and weaker legacy products while lifting 2026 outlook.